Figure 1From: A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesPharmacodynamic relationships following treatment with dinaciclib. Relationship between percentage of bromodeoxyuridine uptake (relative to baseline) and dinaciclib plasma concentration (A), and best percentage change in maximum standard uptake value (SUVmax) determined by PET/CT scan (B) for subjects administered 0.33 to 14.0Â mg/m2 doses of dinaciclib.Back to article page